Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Gains from Sales and Divestitures (2016 - 2021)

Historic Gains from Sales and Divestitures for Medifast (MED) over the last 7 years, with Q3 2021 value amounting to $26000.0.

  • Medifast's Gains from Sales and Divestitures fell 1333.33% to $26000.0 in Q3 2021 from the same period last year, while for Sep 2021 it was $26000.0, marking a year-over-year decrease of 1333.33%. This contributed to the annual value of $32000.0 for FY2020, which is 8829.13% down from last year.
  • According to the latest figures from Q3 2021, Medifast's Gains from Sales and Divestitures is $26000.0, which was down 1333.33% from $25000.0 recorded in Q2 2021.
  • In the past 5 years, Medifast's Gains from Sales and Divestitures ranged from a high of $273300.0 in Q4 2019 and a low of $14000.0 during Q1 2021
  • For the 5-year period, Medifast's Gains from Sales and Divestitures averaged around $78987.6, with its median value being $32000.0 (2019).
  • Over the last 5 years, Medifast's Gains from Sales and Divestitures had its largest YoY gain of 20032.97% in 2019, and its largest YoY loss of 9000.0% in 2019.
  • Medifast's Gains from Sales and Divestitures (Quarter) stood at $120000.0 in 2017, then dropped by 24.17% to $91000.0 in 2018, then surged by 200.33% to $273300.0 in 2019, then crashed by 88.29% to $32000.0 in 2020, then decreased by 18.75% to $26000.0 in 2021.
  • Its Gains from Sales and Divestitures was $26000.0 in Q3 2021, compared to $25000.0 in Q2 2021 and $14000.0 in Q1 2021.